Insights Into Myelofibrosis (MF)
Perspectives on drivers in treatment decisions in the management of myelofibrosis (MF)
Faculty Chair
Prithviraj Bose, MD
MD Anderson Cancer Center
Faculty Chair
John Mascarenhas, MD
The Mount Sinai Hospital
Faculty Chair
John Mascarenhas, MD
The Mount Sinai Hospital
Faculty Chair
John Mascarenhas, MD
The Mount Sinai Hospital
Faculty Chair
Kristen Pettit, MD
C.S. Mott Children's Hospital
Faculty Chair
Srdan Verstovsek, MD, PhD
MD Anderson Cancer Center
Faculty Chair
Srdan Verstovsek, MD, PhD
MD Anderson Cancer Center
Faculty Chair
Kristen Pettit, MD
C.S. Mott Children's Hospital
Faculty Chair
Kristen Pettit, MD
C.S. Mott Children's Hospital
Faculty Chair
Elias Jabbour, MD
MD Anderson Cancer Center
Faculty Chair
John Mascarenhas, MD
The Mount Sinai Hospital
Faculty Chair
John Mascarenhas, MD
The Mount Sinai Hospital
Faculty Chair
John Mascarenhas, MD
The Mount Sinai Hospital
Faculty Chair
John Mascarenhas, MD
The Mount Sinai Hospital
Faculty Chair
John Mascarenhas, MD
The Mount Sinai Hospital
Faculty Chair
Rami Komrokji, MD
Moffitt Cancer Center
Faculty Chair
Jonathan Abbas, MD
Tennessee Oncology
Faculty Chair
Pankit Vachhani, MD
University of Alabama
Faculty Chair
John Mascarenhas, MD
The Mount Sinai Hospital
Faculty Chair
John Mascarenhas, MD
The Mount Sinai Hospital
More Information
- Virtual series
- Gulf region
More Information
- Virtual series
- Midwest region
More Information
- Virtual series
- Northeast region
More Information
- Virtual series
- Midwest region
More Information
- Virtual series
- Northeast region
More Information
- Virtual series
- Northeast region
More Information
- Virtual series
- Ohio Valley region
More Information
- Virtual series
- West region
More Information
- Virtual series
- West region
More Information
- Virtual series
- Ohio Valley region
More Information
- Virtual series
- Midwest region
More Information
- Virtual series
- Ohio Valley region
More Information
- Virtual series
- Gulf region
More Information
- Virtual series
- Southeast
More Information
- Virtual series
- Gulf region
More Information
- Virtual series
- Mid-Atlantic region
More Information
- Virtual series
- Southeast
More Information
- Virtual series
- Mid-Atlantic region
More Information
- Virtual series
- Mid-Atlantic region
More Information
- Virtual series
- Southeast
More Information
- Virtual series
- Florida Cancer Specialists
More Information
- Virtual series
- Tennessee Oncology
More Information
- Virtual series
- University of Alabama
More Information
- Virtual series
- New York Cancer & Blood Specialists
More Information
- Virtual series
- Zangmeister
More Information
- Virtual series
- TOPA
REPORT SNAPSHOT
- A virtual, moderated roundtable discussion focusing on the treatment of MF
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained
- Current management and emerging challenges in MF
- Current therapy paradigms for MF
- Unmet needs and emerging paradigms
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region
